Načítá se...
Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points
Venetoclax (VEN), a small-molecule inhibitor of B cell leukemia/lymphoma-2, is now FDA approved (November 2018) for use in acute myeloid leukemia (AML), specific to newly diagnosed elderly or unfit patients, in combination with a hypomethylating agent (HMA; including azacitidine or decitabine) or lo...
Uloženo v:
| Vydáno v: | Blood Cancer J |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Nature Publishing Group UK
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7684277/ https://ncbi.nlm.nih.gov/pubmed/33230098 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-020-00388-x |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|